Status:
COMPLETED
Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma
Lead Sponsor:
Samsung Medical Center
Conditions:
Hepatocellular Carcinoma
Obstructive Jaundice
Eligibility:
All Genders
19-70 years
Phase:
NA
Brief Summary
The prognosis of patients with obstructive jaundice caused by hepatocellular carcinoma (HCC) is dismal even after biliary drainage; due to malfunction of the biliary drainage tube caused by hemobilia ...
Detailed Description
As more therapies are available for patients with hepatocellular carcinoma (HCC), the survival rate has improved. The incidence of jaundice in patients with HCC is reported as 5-44%, and substantial n...
Eligibility Criteria
Inclusion
- Known HCC: Diagnosis of HCC based on the 2005 AASLD (American Association for the Study of Liver Diseases) practice guidelines
- Unresectable HCC: Determined based on the BCLC (Barcelona-Clinic-Liver-Cancer) staging and treatment system
- Bile duct invasion of HCC: Confirmed by pathology via endoscopic retrograde cholangiopancreatogram (ERCP) or percutaneous transhepatic biliary drainage (PTBD). In case pathological diagnosis is clinically impossible, confirmed by dynamic CT or MRI showing that typical arterial enhancing mass in dilated bile duct and previous HCC diagnosis.
Exclusion
- Severe renal disease
- Severe cardiac disease
- Bleeding tendency
- Porphyria
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01506115
Start Date
September 1 2009
End Date
March 1 2011
Last Update
November 20 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center 81 Irwon-Ro Gangnamgu
Seoul, South Korea, 06351